Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287800 · ClinicalTrials.gov registry record · Phase 1
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
A Phase 1 study of Kidney Transplant and Hypogonadism, Male, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07287800 is a Phase 1 study of Kidney Transplant and Hypogonadism, Male that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 50 participants, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07287800, a Phase 1 study of Kidney Transplant and Hypogonadism, Male, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective study aims to evaluate the safety and efficacy of testosterone replacement therapy (TRT) as an adjunct to an enhanced recover after surgery (ERAS) protocol in men with end-stage renal disease (ESRD) undergoing kidney transplantation. Participants will be highly-listed hypogonadal men, defined as total testosterone level \<300 on two occasions with clinical symptoms of hypogonadism, with ESRD who are expected to receive a kidney transplant within 6 months. Participants will be started on TRT, ideally for at least 3 months prior transplantation. The investigators will perform a subset analysis to evaluate if there is a significant difference in our endpoints by comparing these two subgroups (Three months or more receiving TRT vs. Less than three months receiving TRT). There will be no cut-off time for pre-transplant TRT. Following the intervention period, a historical control cohort of age-matched and health-matched patients will be identified, who have followed a standard transplant protocol that does not incorporate TRT. The primary outcome will evaluate safety, including 30- and 90-day adverse events, 3, 6, and 12-month allograft survival, and overall patient survival. Secondary outcomes will focus on (1) qualitative assessments of symptoms using validated questionnaires, (2) quantitative improvements in the hormonal profile before and after initiation of TRT and surgery, and (3) allograft function and incidence of delayed graft function. The results of this study could provide novel insights into the benefits of TRT in improving surgical outcomes in men with ESRD undergoing kidney transplantation.
Conditions Studied
Interventions
- DRUG Testosterone Replacement Therapy
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07287800
The ClinicalTrials.gov registry entry for NCT07287800 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Replacement Therapy is the first listed.
NCT07287800 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07287800 about?
NCT07287800 is a clinical study titled "TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation". This prospective study aims to evaluate the safety and efficacy of testosterone replacement therapy (TRT) as an adjunct to an enhanced recover after surgery (ERAS) protocol in men with end-stage renal disease (ESRD) undergoing kidney transplantation. Participants will be highly-listed hypogonadal m...
What is the current status of trial NCT07287800?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-07-01. Estimated completion is 2027-06.
What conditions does trial NCT07287800 study?
This clinical trial studies the following conditions: Kidney Transplant, Hypogonadism, Male, End Stage Renal Disease (ESRD).
What interventions are being tested in trial NCT07287800?
The interventions under investigation include: Testosterone Replacement Therapy (DRUG).
Who is sponsoring clinical trial NCT07287800?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287800 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
RECRUITING · Phase 1
-
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
RECRUITING · Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.